The identification of myelin protein zero as an important autoantigen (Ag) in CIDP may suggest the development of Ag-based therapies, such as Ag-specific DNA vaccination or infusion of Ag-coupled cells. Here, RENBP is linked to chronic inflammatory demyelinating polyradiculoneuropathy.